Abstract | Background: Methods: A 6-months observational real life study was performed involving psoriasis patients. Inclusion criteria were age ≥ 18 years, moderate-to-severe psoriasis diagnosis since at least 1 year, patients being on biologic treatment for psoriasis ≥ 6 months. A 14-item questionnaire was administered to all patients enrolled to assess whether the patient ever experienced ISRs after the injection of the biologic drug. Results: 234 patients were included: 32.5% received an anti- TNF-alpha drug, 9.4% received anti- IL12/23, 32.5% received an anti-IL17, 25.6% received an anti-IL23. 51.2% of study population reported at least one symptom related to ISR. 35.9% of patients experienced pain, 31.6% swelling, 28.2% burning sensation and 17.9% erythema. 3.4% of the surveyed population experienced anxiety or fear of the biologic injection due to ISRs symptoms. The greater incidence of pain was registered in anti- TNF-alpha and anti-IL17 groups (47.4% and 42.1%, p<0.01). Ixekizumab proved to be the drug with the highest rate of patients experiencing pain (72.2%), burning (77.7%) and swelling (83.3%). No patients reported biologics discontinuation or delay for ISRs symptoms. Conclusion: Our study highlighted that each different class of biologics for psoriasis was linked to ISRs. These events are more frequently reported with anti- TNF-alpha and anti-IL17.
|
Authors | Matteo Megna, Teresa Battista, Matteo Noto, Vincenzo Picone, Gabriella Fabbrocini, Angelo Ruggiero, Lucia Genco |
Journal | Clinical, cosmetic and investigational dermatology
(Clin Cosmet Investig Dermatol)
Vol. 16
Pg. 553-564
( 2023)
ISSN: 1178-7015 [Print] New Zealand |
PMID | 36896374
(Publication Type: Journal Article)
|
Copyright | © 2023 Megna et al. |